| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer | See Remarks | SVP Chief Commercial Officer
2 companies
Edwards Larry Todd is a See Remarks at ARQT, with reported holdings spanning 2 companies. Recent filings cover 1 purchase and 10 sales. Those positions are worth an estimated $4.5M at current prices.
Our model assigns Edwards Larry Todd a below-average insider score of 36/100, based on 7 past trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -37.3%.
Edwards Larry Todd's largest disclosed position is in ARQT as See Remarks, worth about $4.5M. The recent filings there lean toward selling, a net 59,270 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | ARQT Arcutis Biotherapeutics, Inc. | See Remarks | Sell | 3,687 | $25.18 | $92,846.26 | -2.1% | -13.3% | - | |
| Feb 2, 2026 | ARQT Arcutis Biotherapeutics, Inc. | See Remarks | Sell | 2,052 | $25.50 | $52,322.72 | -1.4% | -8.1% | - | |
| Nov 6, 2025 | ARQT Arcutis Biotherapeutics, Inc. | See Remarks | Sell | 29,131 | $25.16 | $732,927.22 | -16.2% | +3.9% | - | |
| Oct 2, 2025 | ARQT Arcutis Biotherapeutics, Inc. | See Remarks | Sell | 4,504 | $20.04 | $90,263.31 | -2.5% | +36.7% | +18.4% | |
| May 19, 2025 | ARQT Arcutis Biotherapeutics, Inc. | See Remarks | Sell | 7,451 | $14.07 | $104,849.73 | -3.9% | +14.3% | +33.2% | |
| Feb 3, 2025 | ARQT Arcutis Biotherapeutics, Inc. | See Remarks | Sell | 2,173 | $12.70 | $27,597.10 | -1.6% | +21.4% | +106.4% | |
| Nov 30, 2024 | ARQT Arcutis Biotherapeutics, Inc. | See Remarks | Buy | 1,093 | $7.11 | $7,766.86 | +0.8% | +5.0% | +132.9% | |
| Oct 2, 2024 | ARQT Arcutis Biotherapeutics, Inc. | SVP Chief Commercial Officer | Sell | 3,725 | $10.01 | $37,295.45 | -2.7% | +36.2% | +107.7% | |
| May 17, 2024 | ARQT Arcutis Biotherapeutics, Inc. | SVP Chief Commercial Officer | Sell | 7,640 | $8.98 | $68,581.99 | -5.2% | -7.6% | +53.4% |